NEW YORK – Beckman Coulter Diagnostics announced on Tuesday that it has entered a strategic partnership with Israeli diagnostic company MeMed to develop and commercialize a host immune response diagnostic test.
Under the agreement, Brea, California-based Beckman Coulter will develop and co-promote the MeMed BV test for use with Beckman Coulter's Access line of immunoassay analyzers, the companies said in a statement. Financial terms of the deal were not disclosed.
The test distinguishes between bacterial and viral infections by measuring three host-immune proteins — TRAIL, IP-10, and C-reactive protein — and combining the measurements into a machine learning-based score that indicates the likelihood of one kind of infection.
"The ability to distinguish between bacterial and viral infections early in the diagnostic process has significant potential to impact patient care, as well as combat antimicrobial resistance," Julie Sawyer Montgomery, president of Beckman Coulter, a Danaher business, said in a statement.
The assay has been validated on the MeMed Key immunoassay platform and has received CE marking and 510(k) clearance from the US Food and Drug Administration. Haifa, Israel-based MeMed previously inked a licensing deal in 2020 with DiaSorin to commercialize the test on the Liaison analyzer system. The Liaison version of the test received FDA clearance last year.